|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2008-8-13
|
|
pubmed:abstractText |
Adenoid cystic carcinoma (ACC) can often be controlled with surgery and postoperative adjuvant radiotherapy but is also characterized by late local recurrence and distant metastasis. No effective systemic therapeutic agents have been found to alter the natural history of ACC. Therefore, new therapeutic approaches are needed. In this study, we evaluated whether vandetanib (Zactima), a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinases, had antitumor efficacy in vitro and in an orthotopic nude mouse model of human ACC.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5081-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18698025-Animals,
pubmed-meshheading:18698025-Antineoplastic Agents,
pubmed-meshheading:18698025-Apoptosis,
pubmed-meshheading:18698025-Blotting, Western,
pubmed-meshheading:18698025-Carcinoma, Adenoid Cystic,
pubmed-meshheading:18698025-Cell Line, Tumor,
pubmed-meshheading:18698025-Cell Proliferation,
pubmed-meshheading:18698025-Fluorescent Antibody Technique,
pubmed-meshheading:18698025-Humans,
pubmed-meshheading:18698025-Immunohistochemistry,
pubmed-meshheading:18698025-In Situ Nick-End Labeling,
pubmed-meshheading:18698025-Male,
pubmed-meshheading:18698025-Mice,
pubmed-meshheading:18698025-Mice, Nude,
pubmed-meshheading:18698025-Parotid Neoplasms,
pubmed-meshheading:18698025-Phosphorylation,
pubmed-meshheading:18698025-Piperidines,
pubmed-meshheading:18698025-Quinazolines,
pubmed-meshheading:18698025-Receptor, Epidermal Growth Factor,
pubmed-meshheading:18698025-Vascular Endothelial Growth Factor Receptor-2,
pubmed-meshheading:18698025-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
|
|
pubmed:affiliation |
Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
